T. Oliver

4.7k total citations · 2 hit papers
20 papers, 3.4k citations indexed

About

T. Oliver is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, T. Oliver has authored 20 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 11 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in T. Oliver's work include Testicular diseases and treatments (7 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Sarcoma Diagnosis and Treatment (5 papers). T. Oliver is often cited by papers focused on Testicular diseases and treatments (7 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Sarcoma Diagnosis and Treatment (5 papers). T. Oliver collaborates with scholars based in United Kingdom, Denmark and United States. T. Oliver's co-authors include Luigi Dogliotti, Hans von der Maase, J.T. Roberts, Malcolm J. Moore, M. Arning, Annamaria H. Zimmermann, Sergio Ricci, Lisa Sengeløv, Peter Albers and D. Roychowdhury and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and British Journal of Cancer.

In The Last Decade

T. Oliver

17 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

2000 1.7k citations Hans von der Maase, Steen Werner Hansen et al. Journal of Clinical Oncology profile →
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

2005 1.4k citations Hans von der Maase, Lisa Sengeløv et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T. Oliver United Kingdom	8	2.8k	1.2k	646	576	360	20	3.4k
Jean Hoffman‐Censits United States	24	2.4k 0.9×	1.2k 1.0×	919 1.4×	870 1.5×	368 1.0×	153	3.4k
Anna Orsola Spain	26	1.3k 0.5×	645 0.5×	802 1.2×	359 0.6×	385 1.1×	64	2.2k
Andrew T. Lenis United States	18	1.2k 0.4×	399 0.3×	652 1.0×	674 1.2×	232 0.6×	77	2.1k
Yong‐Tae Kim South Korea	32	1.8k 0.6×	1.7k 1.5×	1.2k 1.8×	541 0.9×	92 0.3×	154	3.0k
Fabio Calabrò Italy	24	680 0.2×	689 0.6×	950 1.5×	386 0.7×	152 0.4×	96	1.9k
K.C. Balaji United States	27	658 0.2×	481 0.4×	727 1.1×	1.1k 1.8×	290 0.8×	85	2.2k
Roland Sonntag Switzerland	20	732 0.3×	471 0.4×	422 0.7×	485 0.8×	91 0.3×	48	1.5k
Minyong Kang South Korea	23	583 0.2×	475 0.4×	684 1.1×	513 0.9×	207 0.6×	156	1.8k
Tibor Szarvas Germany	30	936 0.3×	503 0.4×	575 0.9×	825 1.4×	308 0.9×	155	2.3k
Robert P. Huben United States	24	870 0.3×	397 0.3×	894 1.4×	351 0.6×	166 0.5×	79	2.0k

Countries citing papers authored by T. Oliver

Since Specialization

Citations

This map shows the geographic impact of T. Oliver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Oliver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Oliver more than expected).

Fields of papers citing papers by T. Oliver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Oliver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Oliver. The network helps show where T. Oliver may publish in the future.

Co-authorship network of co-authors of T. Oliver

This figure shows the co-authorship network connecting the top 25 collaborators of T. Oliver. A scholar is included among the top collaborators of T. Oliver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Oliver. T. Oliver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Hale, Andrew T., Cody Savage, Dagoberto Estévez-Ordoñez, et al.. (2025). Epilepsy surgery outcomes in children with tuberous sclerosis complex: a systematic review and meta-analysis. Journal of Neurosurgery Pediatrics. 35(6). 599–611.

2.

Oliver, T., et al.. (2024). 196 Quantifying Cholinergic Cortical Response to Deep Brain Stimulation in Murine Models. Neurosurgery. 70(Supplement_1). 50–51.

3.

Maase, Hans von der, Steen Werner Hansen, J.T. Roberts, et al.. (2023). Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. Journal of Clinical Oncology. 41(23). 3881–3890. 19 indexed citations

4.

Oliver, T., et al.. (2023). The Inferior Temporal Gyrus Approach to Mesial Basal Temporal Lobe Surgery: 2-Dimensional Operative Video. Operative Neurosurgery. 26(4). 472–473.

5.

Lawrence, Thomas, et al.. (2018). Thermal comfort evaluation in campus classrooms during room temperature adjustment corresponding to demand response. Building and Environment. 148. 488–497. 89 indexed citations

6.

Shamash, Jonathan, Tom Powles, Peter Wilson, et al.. (2007). A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Annals of Oncology. 18(5). 925–930. 22 indexed citations

7.

Powles, Tom, et al.. (2007). The long term side effects of adjuvant carboplatin for stage 1 seminoma. Journal of Clinical Oncology. 25(18_suppl). 5089–5089. 1 indexed citations

8.

Maase, Hans von der, L. Sengeløv, John Roberts, et al.. (2006). UROLOGICAL ONCOLOGY: BLADDER, PENIS AND URETHRA CANCER, AND BASIC PRINCIPLES OF ONCOLOGY Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer. 1 indexed citations

9.

Oliver, T., et al.. (2006). Phase II screening study to assess the combination of a LHRH analogue, dexamethasone and a somatostatin analogue versus a LHRH analogue with dexamethasone in hormone refractory prostate cancer patients. Journal of Clinical Oncology. 24(18_suppl). 4565–4565. 1 indexed citations

10.

Maase, Hans von der, L. Sengeløv, J.T. Roberts, et al.. (2006). Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients with Bladder Cancer. The Journal of Urology. 175(2). 482–482. 112 indexed citations

11.

Oliver, T., K.‐P. Dieckmann, H Steiner, & Iwona Skoneczna. (2005). Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma. Journal of Clinical Oncology. 23(16_suppl). 4572–4572. 5 indexed citations

12.

Maase, Hans von der, Lisa Sengeløv, J.T. Roberts, et al.. (2005). Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer. Journal of Clinical Oncology. 23(21). 4602–4608. 1358 indexed citations breakdown →

13.

Powles, Tom, Mark Bower, Jonathan Shamash, et al.. (2004). Outcome of patients with HIV-related germ cell tumours: a case–control study. British Journal of Cancer. 90(8). 1526–1530. 20 indexed citations

14.

Oliver, T., et al.. (2004). 20 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Could it have been accelerated by 72 hr PET scan response?. Journal of Clinical Oncology. 22(14_suppl). 4763–4763. 3 indexed citations

15.

Oliver, T., et al.. (2004). 20 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Could it have been accelerated by 72 hr PET scan response?. Journal of Clinical Oncology. 22(14_suppl). 4763–4763. 1 indexed citations

16.

Verma, Savita, Maureen Trudeau, K.I. Pritchard, & T. Oliver. (2003). The role of the taxanes in the management of metastatic breast cancer. 4 indexed citations

17.

Powles, Tom, Mark Bower, Gedske Daugaard, et al.. (2003). Multicenter Study of Human Immunodeficiency Virus–Related Germ Cell Tumors. Journal of Clinical Oncology. 21(10). 1922–1927. 38 indexed citations

18.

Dawson, L., et al.. (2001). Osteonecrosis of the femoral head following adjuvant chemotherapy for breast cancer. The Breast. 10(5). 447–449. 6 indexed citations

19.

Maase, Hans von der, Steen Werner Hansen, J.T. Roberts, et al.. (2000). Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. Journal of Clinical Oncology. 18(17). 3068–3077. 1678 indexed citations breakdown →

20.

WITHEROW, R. O'N., E. A. MOLLAND, T. Oliver, & C R Hind. (1980). Leiomyosarcoma of prostate and superficial soft tissue. Urology. 15(5). 513–515. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact